From the Research
Approximately 10% of patients present with metastatic prostate cancer, which has a 5-year survival rate of 37%. This advanced stage is characterized by cancer that has spread beyond the prostate to distant sites such as bones, lymph nodes, or other organs. The incidence of metastatic prostate cancer is estimated to be around 29,901 cases per 100,000 men in the United States, with a significant increase in incidence among men aged 70 years and older 1.
Key Points
- The 5-year survival rate for stage 4 prostate cancer is around 37%, though this varies based on individual factors including age, overall health, and response to treatment 2.
- African American men face a higher incidence rate and mortality from stage 4 prostate cancer compared to other racial groups 2.
- The median age at diagnosis is approximately 67 years 2.
- Treatment typically involves systemic approaches such as hormone therapy (androgen deprivation therapy), chemotherapy, immunotherapy, or targeted therapies rather than localized treatments 2.
- Early detection through regular PSA screening and digital rectal exams remains crucial for preventing progression to stage 4 disease, as prostate cancer caught in earlier stages has significantly better outcomes and treatment options 2.
Incidence and Survival
- The incidence of distant stage prostate cancer significantly increased during 2010-2017, with an estimated annual percentage change of 6.4% 3.
- The 10-year relative survival for localized stage prostate cancer was 100% during 2001-2016, while the 5-year survival for distant stage prostate cancer improved from 28.7% during 2001-2005 to 32.3% during 2011-2016 4.
- Understanding incidence and survival differences by stage, race/ethnicity, and age can guide public health planning related to screening, treatment, and survivor care 4.